May 28, 2021

Featuring perspectives from Dr Jennifer Woyach, including the following topics:

• Front-line therapy for chronic lymphocytic leukemia (CLL) for fellows; use of prognostic biomarkers and cytogenetics in refining risk assessment for patients with newly diagnosed disease — Jennifer Woyach, MD (0:00)
• Bruton tyrosine kinase (BTK) inhibitors for treatment-naïve CLL (8:29)
• Venetoclax/obinutuzumab for treatment-naïve disease; overview of patient selection for chemoimmunotherapy (18:04)
• Relevant biomarkers influencing the selection of therapy for patients with CLL (24:09)
• Impact of biologic and patient-related factors on front-line decision-making (30:24)
• Selection and sequencing of therapies for relapsed/refractory CLL (1:02:53)
• Key considerations and take-home messages (1:13:52)

CME information and select publications